Illumina

San Diego, California, United States

Drug Discovery/Development Precision Medicine/DiagnosticsIPO

Illumina is involved in genomics and drug discovery, collaborating with NVIDIA for sequencing and multiomics analysis.

✓Source: HealthTech Alpha by Galen Growth

Shareable draft

Check out Illumina on @MedStartr Today Illumina is involved in genomics and drug discovery, collaborating with NVIDIA for sequencing and multiomics analysis. #GeneticAndRareDiseases #SexualReproductiveHealth #InfectiousDiseases #CancerOncology #DrugDiscoveryDevelopment #PrecisionMedicineDiagnostics #MedMo #MedStartrVentures

https://www.medstartr.ai/s/QTbYNt4i3vc

Note, this image was autogenerated by Syggy based on what we know about the company. It is not an official company publication.

Get Involved in Illumina

1 engagement

How We Help

Problem Statement

Illumina solves the challenge of accurately and efficiently analyzing genetic variation and biological function to advance genomics research, clinical applications, and personalized medicine.

Core Technology

Genomics, sequencing, multiomics analysis

Key Differentiators

Market Leadership and Scale; Proprietary and Accurate Technology (Sequencing by Synthesis (SBS) technology, XLEAP-SBS chemistry); Integrated Ecosystem (sequencers, reagents, bioinformatics software like DRAGEN and BaseSpace, global service network); Cost-Efficiency for High-Volume Projects; Broad Application Range; Global Presence and Support.

Clinical Focus

Enabling applications like whole-genome sequencing, genotyping, gene expression and transcriptome profiling, and epigenetics for various clinical areas.

Target Customers

Researchers, clinicians, diagnostic laboratories, pharmaceutical companies, and institutions involved in personalized medicine, oncology, genetic diseases, infectious diseases, and reproductive health.

Product Stage

Mature

Company Info

Business Model: B2B, razor-and-blade model, sale of integrated systems (sequencing platforms, microarrays) and consumables, software and service subscriptions.
Founded: 2013
Total Funding: Only accessible to MedStartr community members. Join now
Only accessible to MedStartr community members.
Join now
Website: www.illumina.com/

Disease Areas

Genetic and Rare Diseases Reproductive Health Infectious Diseases Cancer & Oncology

Technologies

Sequencing by Synthesis (SBS)Microarray TechnologyDRAGEN Secondary Analysis SoftwareGenomicsBioinformaticsGenetic AnalysisXLEAP-SBS ChemistryNext-Generation Sequencing

🌐Website

MedStartr Engagement Score

The MedStartr Index is a reflection of how the crowds that come to MedStartr everyday to find healthcare innovations reacted. Calculated by our AI agent Fyggy based on algorithms we have been building since 2012 and over 100 different factors, the math is proprietary and complex. Suffice to say, it has been found to be highly correlative with early stage company growth. What you see here is the public version. To learn more or to get deeper access to our predictive data on startup success for your fund or company, click here.

Comments

Comments from new members are shown once the company's team has approved them. Please follow the community rules.

Be the first to comment.

What do you think of Illumina?

A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.

Clinical Benefit Potential

The potential for a project to have a large and significant impact on medical care, treatment, or prevention.

Feasibility

The likelihood that this will provide benefit for patients / care givers and that the founders can execute on their vision and plan.

Innovativeness

The distinguishing features, concept, or technology that differentiates the entry compared to others that already exist and are in widespread use.

Fundability

The reviewers' beliefs that the idea is fundable or can make it to sustainability without outside investment.

Scalability

Some great ideas are destined to failure because they are too complex or too expensive. The reviewer should consider the likelihood that a project as explained, or perhaps with some tweaks, could possibly become a worldwide solution within a reasonable time frame.

Presentation Quality

How well the team presented the idea.

Submit anonymously — my name won't be shown to the team or on this profile

Your scores and comments are shown with your review on this company's profile.